Benchmark Electronics Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 18% revenue growth and 36% EPS growth, both above guidance, with strong performance in Semi-Cap, Industrial, Medical, and AC&C sectors. The 2026 revenue outlook was raised to $3 billion, and operational execution and supply chain management remain key priorities.
-
Q1 revenue and EPS exceeded guidance, driven by strong execution and broad-based sector growth. Full-year outlook was raised, with Semi-Cap, Medical, and AC&C showing notable momentum, and continued operational discipline supporting margin expansion.
-
Management highlighted a shift toward higher-margin sectors, ongoing investments in Semi-Cap and AI, and stable growth in industrial and medical markets. Operating margin and free cash flow targets remain strong, with disciplined capital allocation and potential for increased M&A activity.
-
Leadership transition is underway with new commercial and technical leaders in place. Sector outlooks are positive, especially for semi-cap equipment and AI-driven opportunities, while financial performance remains strong with improved margins and disciplined capital allocation.
Fiscal Year 2025
-
Q4 2025 saw 7% revenue growth and strong performance in AC&C, Medical, and A&D, with gross margin above 10%. Full-year revenue was flat, but momentum improved in the second half. 2026 guidance calls for mid-single-digit growth, with Semi-Cap and Medical sectors expected to lead.
-
Q3 2025 saw revenue and EPS at the high end of guidance, with broad-based sector growth and strong cash flow. Medical and A&D led with double-digit gains, while Semicap faces near-term softness but is expected to recover in late 2026. AI and automation investments support future growth.
-
Leadership transition is underway with a focus on accelerating growth strategies across key sectors. Bookings and margins are improving, driven by sector wins, operational optimization, and a disciplined approach to new business. AI and advanced technology remain growth drivers.
-
Q2 2025 saw revenue and EPS at guidance midpoints, with gross margin above 10% for the seventh straight quarter. Strong bookings and sector wins support a positive outlook for H2 2025, while cash flow and inventory management continue to improve.
-
Maintained strong gross margins and free cash flow, with sector shifts favoring semi-cap and aerospace & defense. Expansion in Penang and focus on operational efficiency position for growth, while limited China exposure and disciplined capital allocation support resilience.
-
Q1 2025 saw $632M revenue with strong Semi-Cap and A&D growth, but overall revenue declined YoY and sequentially. Gross margin remained above 10% and free cash flow was positive. Second half 2025 is expected to return to growth, with ongoing investments in capacity and supply chain flexibility.
-
Management highlighted strong sector diversification, with growth in semiconductor capital equipment and resilience in aerospace and defense. Industrial is stabilizing, while medical and advanced computing face near-term headwinds. Operational discipline and targeted capital allocation support margin expansion and free cash flow.
Fiscal Year 2024
-
Q4 and FY24 saw margin expansion and strong free cash flow despite revenue declines, with semi-cap and A&D driving growth while medical and AC&C lagged. 2025 guidance anticipates revenue and earnings growth, continued capital investment, and sector recovery, especially in semi-cap and A&D.
-
The company highlighted its diversified sector exposure, global manufacturing and design footprint, and focus on high-value, complex markets. Aerospace, defense, and semiconductor capital equipment are key growth drivers, while robust free cash flow and disciplined capital allocation support ongoing investments and margin expansion.
-
Q3 results exceeded guidance with strong margins and cash flow, led by semicap and aerospace & defense growth, while medical and AC&C sectors remained weak. Guidance for Q4 anticipates stable margins and continued positive free cash flow, with sector recovery expected in 2025.
-
Management highlighted a strategic shift to high-complexity, regulated sectors, outperforming margin and cash flow targets despite macro challenges. Growth is driven by operational efficiencies, sector diversification, and a strong global footprint, with optimism for semi-cap, A&D, and future CHIPS Act benefits.
-
Q2 revenue and margins exceeded guidance, led by strong A&D and SemiCap performance, while Medical and AC&C remained weak. Free cash flow and inventory management improved, with a raised 2024 cash flow outlook and increased dividend. Growth investments continue in key regions.